

## 2022 Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae Multi-site Gram-Negative Surveillance Initiative (MuGSI) Healthcare-Associated Infections Community Interface (HAIC) Case Report

Form Approved OMB No. 0920-0978

Patient's Name	e:					Р	hone no.:				
Address:								MRN:			
Address Type:								Hospital	:		
			Patient Id	lentifier infor	mation is n	ot transmit	ted to CDC				
DEMOGRAPH	IICS										
1. STATE:	2. COUNTY:	3. STATE ID:				ATORY ID W SPECIMEN I		4b. FACIL	ITY ID WHERE P	PATIENT	TREATED:
5. DATE OF BIRT  6. AGE:  O Days		7. SEX AT BIF O Male O Female O Unknown Check if tra		8a. ETHNIC O OHispanic or ONot Hispani OUnknown	Latino	☐ America	(Check all that n Indian or Alas African America	ka Native	□Native Hawaii □White □Unknown	an or Oth	er Pacific Islander
	DENT SPECIMEN (DISC): (mm/dd/yyyy)	○ Esche		<b>Cephalospori</b> niae	n-resistant:						
☐ Blood ☐ Bone ☐	PECIMEN COLLECTION Internal body site (special special				Peritoneal flui Pericardial flui Pleural fluid			terile site (spe	ecify):		
12. LOCATION C	F SPECIMEN COLLECT	ION:			13. WHERE	WAS THE PA	ATIENT LOCAT	ED ON THE	3RD CALENDAR	R DAY BE	FORE THE DISC?
O OUTPATIENT Facility ID:	•	IENT :	OLTCF Facility ID:		O Private re O LTCF Facility I			_	TACH acility ID:		
O Emergenc O Clinic/Doc O Dialysis ce O Surgery	tor's office OR nter Rac		OLTACH Facility ID:		O Hospital Facility II			Õln	omeless carcerated ther (specify):		
Observation Clinical de O Other outp	cision unit	·	Other (Sp		Was the this hos OYes	patient trans pital? ONo	ferred from  OUnknow		nknown		
			OUnknow	n							
14. WAS THE PATIENT HOSPITALIZED ON THE DAY OF OR IN THE 29 CALENDAR DAYS AFTER THE DISC?  O Yes O No OUnknown					<b>15a. WAS 1</b> O Yes	No No	O Unknown	THE 7 DAYS	BEFORE THE DI	ISC?	
O Yes	O No OUNKNO	own			IF YES, DATE	OF ICU ADM	ISSION: (mm/dd/	<sup>/</sup> уууу)		OR	☐ Date unknown
IF YES, DATE OF ADMISSION: (mm/dd/yyyy)							IN AN ICU ON N THE 6 DAYS		F INCIDENT SPI DISC?	ECIMEN	
						_	_	/уууу)		OR	☐ Date unknown
16. PATIENT OUT	COME: O Survived			(	Died				OUnknown		
_	HARGE: (mm/dd/yyyy)		OR		OATE OF DEAT	H: (mm/dd/yyy)	y)	OR	☐ Date unknow	vn	
O Date unkno	own C	Left against medic	cal advice (AN	(					DEATH, WAS THE I		N
O Private resid	dence C	Other (specify):		(	) Yes	O No	O Unknowr	า			
OLTCF, Facilit OLTACH, Facil	·	Unknown									
Public reporting b	ourden of this collection o	of information is est	timated to av	erage 28 minute	s per response	, including th	e time for reviev	wing instruct	ions, searching ex	kisting dat	a sources,

Public reporting burden of this collection of information is estimated to average 28 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

17a. TYPES OF INFECTION ASSO	CIATED WITH CULTURE(S): (Check a	III that apply):	ONor	ne OColonize	d O Unknown
☐ Abscess, not skin ☐ AV fistula/graft infection ☐ Bacteremia ☐ Bursitis ☐ Catheter site infection (CVC ☐ Cellulitis ☐ Chronic ulcer/wound (not o	☐ Decubitus/pressure ☐ Empyema ☐ Endocarditis ☐ Epidural abscess ☐ Meningitis ☐ Osteomyelitis	ulcer [ C C C	Pneumonia Pyelonephritis Septic arthritis Septic emboli Septic shock Skin abscess Surgical incision in	☐ Surgical☐ Traumati☐ Urinary t☐ Other (sp	site infection (internal) ic wound ract infection
17b. RECURRENT UTI: OYes	S O No O Unknown				
18. UNDERLYING CONDITIONS:	Check all that apply) O None	O Unkr	nown		
CHRONIC LUNG DISEASE  Cystic fibrosis  Chronic pulmonary disease  CHRONIC METABOLIC DISEASE  Diabetes mellitus  With chronic complications  CARDIOVASCULAR DISEASE  CVA/Stroke/TIA  Congenital heart disease  Congestive heart failure  Myocardial infarction  Peripheral vascular disease (PVD  GASTROINTESTINAL DISEASE  Diverticular disease  Inflammatory bowel disease  Peptic ulcer disease	IMMUNOCOMPROMISED CO  HIV infection  AlDS/CD4 count < 200  Primary immunodeficience Transplant, hematopoietic Transplant, solid organ  LIVER DISEASE  Chronic liver disease Ascites Cirrhosis Hepatic encephalopath Variceal bleeding Hepatitis C Treated, in SVR Current, chronic  MALIGNANCY Malignancy, hematologic	y s stem cell	Cerebra Chronic Dement Epilepsy Multiple Neurop Parkinso Other (s  PLEGIAS/P Hemiple Paraple Quadrip	cognitive deficit cia r/seizure/seizure disorder es clerosis athy on's disease pecify):  ARALYSIS egia gia ellegia	SKIN CONDITION  Burn  Decubitus/pressure ulcer  Surgical wound  Other chronic ulcer or chronic wound  Other (specify):  OTHER  Connective tissue disease  Obesity or morbid obesity  Pregnant  MuGSI CONDITIONS  Urinary tract problems/abnormalities  Premature birth  Spina bifida
Short gut syndrome	☐ Malignancy, solid organ (n ☐ Malignancy, solid organ (n			serum creatinine:mg/D nown or not done	L
19. SUBSTANCE USE SMOKING: (Check all that apply) None Unknown Tobacco E-nicotine delivery system Marijuana ALCOHOL ABUSE Yes No Unknown	OTHER SUBSTANCES: (Check all that a	oking)  done, oxycodone)  FION, DID THE F	DUD/ ABUSE  DUD or abuse DUD or abuse DUD or abuse DUD or abuse DUD or abuse DUD or abuse DUD or abuse DUD or abuse DUD or abuse	□ IDU □ Skin popping	/ (Check all that apply)  Non-IDU
20. RISK FACTORS: (Check all tha	nt apply) ONone OUnl	known			
WAS INCIDENT SPECIMEN COLLECT DAYS AFTER HOSPITAL ADMISSION PREVIOUS HOSPITALIZATION IN TH	l? (	Yes ONo	_	OYes ONO OU	LACE ON THE DISC (UP TO THE TIME OF 'TIME IN THE 2 CALENDAR DAYS BEFORE DISC nknown
		_	_	IF YES, CHECK ALL THA ☐ Indwelling Urethral	NT APPLY: Catheter □ Condom Catheter
Facility ID:  OVERNIGHT STAY IN LTCF IN THE Y	EAR BEFORE DISC: (mm/dd/yyyy)	OR, ∐ OYes ONo	OUnknown	Suprapubic Cathete	er Other (specify):  DEVICE IN PLACE ON THE DISC UP TO THE TIME
Facility ID:  OVERNIGHT STAY IN LTACH IN THE	YEAR BEFORE DISC: (	Yes ONo	OUnknown	OYes ONO OL	
Facility ID: SURGERY IN THE YEAR BEFORE DIS	c. (	) Yes O No	OUnknown	☐ ET/NT Tube ☐ Gastrostomy Tube	☐Tracheostomy ☐ Nephrostomy Tube
CURRENT CHRONIC DIALYSIS:		Yes ONG	•	□ NG Tube	Other (specify):
IF YES, TYPE  OHemodialysis  OPeritonea  IF HEMODIALYSIS, TYPE OF VASCU  OAV fistula/graft  CENTRAL LINE IN PLACE ON THE D	I OUnknown JLAR ACCESS: Jysis central line OUnknown	) les () No	Olikilowii		RNATIONALLY IN THE YEAR BEFORE DISC: nknown
OF COLLECTION), OR AT ANY TIME DAYS BEFORE DISC:		Yes O No			WHILE VISITING COUNTRY(IES) ABOVE:
21- WEIGHT.		<u> </u>			
21a. WEIGHT: lbs oz.	OR	21b. HEIGH	<b>I:</b> ft in.	OR	21c. BMI:
kg			_ cm □ Unknow		□Unknown

	before through the 2 calendar days	<b>OCIATED WITH URINE</b> g symptoms were reporte after the DISC.	≤ 1 year of	for patients age only:		
	□None □Unknown □Costovertebral angle pain or ten		mperature ≥ 100.4 °F (38 °C)] cy	☐ Suprapubic tenderness☐ Urgency	□ Apnea □ Bradyca □ Letharg □ Vomitin	у
24a. IS ANTIMICROBIAL U	SE (IV OR ORAL) IN THE 30 DAYS	BEFORE THE DISC DOC	CUMENTED? O Yes O No	OUnknown		
_	NTIMICROBIALS USED IN THE 30	_		Jnknown		
Amikacin Amoxicillin Amoxicillin Ampicillin Ampicillin/sulbactam Azithromycin Aztreonam Cefadroxil Cefazolin Cefdinir Cefepime Cefiderocol Cefixime	☐ Cefotaxime ☐ Cefoxitin ☐ Cefpodoxime ☐ Ceftaroline ☐ Ceftazidime ☐ Ceftazidime/avibactam ☐ Ceftizoxime ☐ Ceftolozane/tazobactam ☐ Ceftriaxone ☐ Cefuroxime ☐ Cephalexin ☐ Ciprofloxacin	Clarithromycin Clindamycin Dalbavancin Daptomycin Delafloxacin Doripenem Doxycycline Ertapenem Eravacycline Fidaxomicin Fosfomycin Gentamicin	Imipenem/cilastatin   Levofloxacin   Linezolid   Meropenem   Meropenem/vaborbactam   Metronidazole   Moxifloxacin   Nitrofurantoin   Omadacycline   Oritavancin   Penicillin   Piperacillin/tazobactam	□ Polymyxin B     □ Polymyxin E (colistin) Ri     □ Tedizolid     □ Telavancin     □ Tigecycline     □ Tobramycin     □ Trimethoprim     □ Trimethoprim/sulfamet     □ IV     □ PO     □ Other (specify):	hoxazole Vancomyc	
	crobial use that is not noted above sh					
TEST) IN THE YEAR BEFOR			Molecular assay	EST TYPE		
25c.COVID-NET CASE ID: 25d. NNDSS IDs: (please p Local case ID: Legacy case identifier:	rovide at least one of the following		own ☐ Antigen ☐ Serology ☐ Unknown ☐ Other (specify):			
25d. NNDSS IDs: (please p	rovide at least one of the following Local record ID: CDC 2019-nCOV ID: SPECIMEN POLYMICROBIAL?	g when applicable)	own Serology Unknown Other (specify):_  ate case identifier:  AT TESTING METHOD WAS USE  y):	.D2	STED, WHAT WAS	THE RESULT?

## **27. SUSCEPTIBILITY RESULTS:**

Please complete the table below based on the information found in the indicated data source.

Antibiotic MIC  Amikacin  Amoxicillin/Clavulanate  Ampicillin  Ampicillin  Ampicillin/Sulbactam  Aztreonam  Cefazolin  CEFEPIME  Cefiderocol  CEFOTAXIME  Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin  MEROPENEM		MIC		MIC		MIC	Interp	MIC	Interp	Zone Diam	Interp	MIC	Interp
Amoxicillin/Clavulanate  Ampicillin  Ampicillin  Ampicillin/Sulbactam  Aztreonam  Cefazolin  CEFEPIME  Cefiderocol  CEFOTAXIME  Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  MIPENEM  mipenem-relebactam  Levofloxacin													
Ampicillin Ampicillin/Sulbactam Aztreonam  Defazolin Defazolin Defiderocol Defiderocol Defoxitin Defoxitin Defoxitin Deftazidime/Avibactam Deftazidime/Avi													
Ampicillin/Sulbactam  Aztreonam  Cefazolin  CEFEPIME  Cefiderocol  CEFOTAXIME  Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  CORIPENEM  COXYCYCline  CRAVACYCLINE  CRAVACYCLINE  CORIPENEM  COSFOMYCIN  COSFOMYCIN  CONTRACT  CONTRACT													
Aztreonam  Cefazolin  Cefazolin  Cefiderocol  CEFOTAXIME  Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  Eravacycline  Certapened  Certapened  Construction  Construction													
Cefazolin CEFEPIME Cefiderocol CEFOTAXIME Cefoxitin CEFTAZIDIME Ceftazidime/Avibactam Ceftolozane/Tazobactam CEFTRIAXONE Cephalothin Ciprofloxacin COLISTIN DORIPENEM Doxycycline Eravacycline ERTAPENEM Fosfomycin Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin													
CEFEPIME  Cefiderocol  CEFOTAXIME  Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
Cefiderocol  CEFOTAXIME  Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
CEFOTAXIME  Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
Cefoxitin  CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
CEFTAZIDIME  Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
Ceftazidime/Avibactam  Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
Ceftolozane/Tazobactam  CEFTRIAXONE  Cephalothin  Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
CEFTRIAXONE Cephalothin Ciprofloxacin COLISTIN DORIPENEM Doxycycline Eravacycline ERTAPENEM Fosfomycin Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin													
Cephalothin Ciprofloxacin COLISTIN DORIPENEM Doxycycline Eravacycline ERTAPENEM Fosfomycin Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin													
Ciprofloxacin  COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
COLISTIN  DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
DORIPENEM  Doxycycline  Eravacycline  ERTAPENEM  Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
Doxycycline Eravacycline ERTAPENEM Fosfomycin Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin													
Eravacycline ERTAPENEM Fosfomycin Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin													
ERTAPENEM Fosfomycin Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin								<b>-</b>					1
Fosfomycin  Gentamicin  IMIPENEM  Imipenem-relebactam  Levofloxacin													
Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin													
Gentamicin IMIPENEM Imipenem-relebactam Levofloxacin													
IMIPENEM Imipenem-relebactam Levofloxacin													
Imipenem-relebactam Levofloxacin													
Levofloxacin													
				1									
Meropenem-vaborbactam													
				-									
Minocycline													
Nitrofurantoin				-									
Omadacycline				-									
Piperacillin/Tazobactam				-									
Plazomicin													
POLYMYXIN B				-			-						
Rifampin													
Tetracycline				ļ									
TIGECYCLINE													
Tobramycin													
Trimethoprim- sulfamethoxazole													
28a. WAS THE CASE FIRST			8b. CRF ST	ΑΤΙΙς.	1					DATE OF:	DOTE - C		
IDENTIFIED THROUGH AN AUD	IT?			A103:		28c	. SO INITIA	LS:	28d.	DATE OF A	ABSTRACTI	ION: (mm/da	/уууу)
O Yes		00	Complete C <mark>omplete-Pe</mark>	ending					-				
ONo		O F	Pending		roguest								
28e. COMMENTS:		Oc	Chart unavai	nable after 3	requests								